Alveofact (with X-ray signs of hyaline membrane disease)
Alveofact (with X-ray signs of hyaline membrane disease) Uses, Dosage, Side Effects, Food Interaction and all others data.
Alveofact (with X-ray signs of hyaline membrane disease) is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized.
In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures. However, in Respiratory Distress Syndrome, developmental deficiency of surfactant results collapse of the alveoli causing fast breathing, increased heart rate, apoxia, and sometimes death. Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. In comparison to synthetic forms of surfacant, natural forms such as Alveofact (with X-ray signs of hyaline membrane disease) have been found to have a reduced incidence of pneumothorax and reduced mortality.
In vitro, Alveofact (with X-ray signs of hyaline membrane disease) reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, it restores pulmonary compliance to excised rat lungs artificially made surfactant-deficient. In vivo, single doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.
Table Of contents
| Trade Name | Alveofact (with X-ray signs of hyaline membrane disease) |
| Availability | Prescription only |
| Generic | Beractant |
| Beractant Other Names | Beractant, Beraksurf |
| Related Drugs | calfactant, Curosurf, Survanta, Infasurf, Surfaxin, lucinactant |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Austria, Colombia, Croatia (Hrvatska), Germany |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Alveofact (with X-ray signs of hyaline membrane disease) is a pulmonary surfactant used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Alveofact (with X-ray signs of hyaline membrane disease) is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Alveofact (with X-ray signs of hyaline membrane disease) is also used to associated treatment for these conditions: Respiratory Distress Syndrome
How Alveofact (with X-ray signs of hyaline membrane disease) works
Alveofact (with X-ray signs of hyaline membrane disease) replenishes lung surfactant and restores surface activity to the lungs by lowering surface tension on alveolar surfaces during respiration and stabilizing the alveoli against collapse at resting transpulmonary pressures.
Food Interaction
No interactions found.Elimination Route
Alveofact (with X-ray signs of hyaline membrane disease) is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface.
Innovators Monograph
You find simplified version here Alveofact (with X-ray signs of hyaline membrane disease)
